Scarica l'app Stockscreener
232.63
0.72%
1.66
Dopo l'orario di chiusura:
232.63
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$230.97
Aprire:
$228.66
Volume 24 ore:
865.23K
Relative Volume:
0.79
Capitalizzazione di mercato:
$25.68B
Reddito:
$11.28B
Utile/perdita netta:
$1.07B
Rapporto P/E:
25.66
EPS:
9.0657
Flusso di cassa netto:
$1.33B
1 W Prestazione:
+0.18%
1M Prestazione:
-1.02%
6M Prestazione:
+21.47%
1 anno Prestazione:
+26.38%
Intervallo 1D:
$228.66
$234.64
Intervallo di 1 settimana:
$226.36
$234.64
Portata 52W:
$171.18
$248.84
Quest Diagnostics Inc Stock (DGX) Company Profile
Nome
Quest Diagnostics Inc
Settore
Industria
Telefono
(973) 520-2700
Indirizzo
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, NTRA, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
232.63 | 25.68B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
662.24 | 244.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
221.20 | 155.50B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
397.77 | 57.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
171.33 | 48.30B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
262.21 | 43.16B | 16.63B | 1.39B | 2.12B | 8.0674 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-01-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | Jefferies | Buy |
| 2024-10-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Ripresa | Evercore ISI | In-line |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2024-02-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-29 | Iniziato | Piper Sandler | Neutral |
| 2023-05-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-23 | Iniziato | Evercore ISI | In-line |
| 2022-11-17 | Downgrade | Citigroup | Neutral → Sell |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-23 | Downgrade | UBS | Buy → Neutral |
| 2022-02-02 | Downgrade | Jefferies | Buy → Hold |
| 2022-01-28 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-03-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Aggiornamento | Argus | Hold → Buy |
| 2020-07-29 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-09 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-04-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2019-04-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-03-18 | Ripresa | Credit Suisse | Neutral |
| 2019-01-31 | Downgrade | Argus | Buy → Hold |
| 2019-01-17 | Iniziato | UBS | Neutral |
| 2019-01-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Quest Diagnostics (NYSE:DGX): A Dividend Quality Pick for Income Investors - ChartMill
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Leerink Partners Adjusts Quest Diagnostics Price Target to $265 From $254 - www.marketscreener.com
Quest Diagnostics Incorporated (DGX) options chain - Yahoo Finance UK
Quest Diagnostics (DGX) Announces Executive Leadership Transitio - GuruFocus
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Catherine T. Doherty to Transition to EVP at Quest Diagnostics, Retirement Set for July 2027 - TradingView
Barclays Adjusts Price Target on Quest Diagnostics to $260 From $250, Keeps Overweight Rating - marketscreener.com
Evercore ISI Adjusts Price Target on Quest Diagnostics to $235 From $240, Keeps In Line Rating - www.marketscreener.com
Quest Diagnostics Inc's Dividend Analysis - Yahoo Finance
Quest Diagnostics (NYSE:DGX) Rides Steady Testing Demand - Kalkine Media
Quest Diagnostics’ Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus - Zacks Investment Research
DGX5874579 Bond Profile: Coupon and Redemption - TradingView
Three Days Left To Buy Quest Diagnostics Incorporated (NYSE:DGX) Before The Ex-Dividend Date - Moomoo
Quest Diagnostics (NYSE:DGX) Breakout Setup Backed by Technical Rating 7 and Setup Rating 8 - ChartMill
Quest Diagnostics (DGX) Highlights Haystack MRD Test Accuracy in Colorectal Cancer Trials - GuruFocus
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally? - TradingView
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally? - Yahoo Finance
Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments - GlobeNewswire Inc.
Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch - Yahoo Finance
Quest Diagnostics shows growth potential despite Medicare uncertainties, driven by testing demand and acquisitions. - Pluang
Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds - Seeking Alpha
Quest Diagnostics Inc (DGX) Stock Down 4.1% but Still Overvalued -- GF Score: 74/100 - GuruFocus
Quest Diagnostics (DGX) Stock Could Be 30% Below Fair Value Following Medicare Payment Cut Concerns - Yahoo Finance
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026 - Yahoo Finance
Why Quest Diagnostics Holdings Stock Dropped Today - Yahoo Finance
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure - Your Wyoming Link
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure - finance.yahoo.com
Quest Diagnostics, Labcorp Shares Fall as Medicare Signals Cuts in Payment Rates for Lab Services - marketscreener.com
Quest Diagnostics, Labcorp Shares Fall as Medicare Signals Cuts in Payment Rates for Lab Services - Yahoo Finance
Is This the Right Time to Add DGX Stock to Your Portfolio? - TradingView
Is This the Right Time to Add DGX Stock to Your Portfolio? - Zacks Investment Research
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Is Quest Diagnostics Stock Outperforming the Nasdaq? - Barchart.com
Is Quest Diagnostics Stock Outperforming the Nasdaq? - Yahoo Finance
Evercore sees Lab Corp, Quest shares facing Medicare pricing headwind By Investing.com - Investing.com Canada
Labcorp, Quest fall as CMS cuts 2027 rates for laboratory services (LH:NYSE) - Seeking Alpha
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges - TradingView
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges - TradingView
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges - Yahoo Finance
Beat the Market Like Zacks: PBF, Palantir, Adobe in Focus - Zacks Investment Research
Nearly 1 in 3 people with Lyme antibodies had others too. A parasite found alongside Lyme needs different treatment. - Stock Titan
Truist Raises Price Target on Quest Diagnostics to $260 From $250, Keeps Hold Rating - marketscreener.com
Quest Diagnostics (DGX) Q1 2026 Earnings Call Transcript - fortune.com
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
96% say lab tests matter as Medicare cuts approach - Stock Titan
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics Inc Azioni (DGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Quest Diagnostics Inc Azioni (DGX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Davis J. E. | Officer |
Sep 01 '26 |
Proposed Sale |
242.72 |
10,000 |
2,427,200 |
0 |
| PREVOZNIK MICHAEL E | SVP & General Counsel |
Aug 28 '26 |
Sale |
243.11 |
22,677 |
5,513,083 |
37,557 |
| PREVOZNIK MICHAEL E | SVP & General Counsel |
Aug 28 '26 |
Option Exercise |
112.17 |
22,677 |
2,543,679 |
60,234 |
| PREVOZNIK MICHAEL E | Officer |
Aug 28 '26 |
Proposed Sale |
243.11 |
22,677 |
5,513,082 |
0 |
| DELANEY MARK E | Officer |
Jul 28 '26 |
Proposed Sale |
235.18 |
1,600 |
376,288 |
0 |
| DELANEY MARK E | SVP & Chief Commercial Officer |
Jul 28 '26 |
Sale |
235.18 |
1,600 |
376,288 |
10,335 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions |
Jun 04 '26 |
Option Exercise |
124.22 |
8,147 |
1,012,000 |
21,657 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions |
Jun 04 '26 |
Sale |
200.00 |
8,147 |
1,629,400 |
13,510 |
| KUPPUSAMY KARTHIK | Officer |
Jun 04 '26 |
Proposed Sale |
200.00 |
8,147 |
1,629,400 |
0 |
| Davis J. E. | CEO and President |
Jun 01 '26 |
Sale |
194.14 |
10,000 |
1,941,400 |
132,423 |
1.08%
2.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):